The purpose of the study is about how the gut microbiome can affect inflammation in people with coronary artery disease. The researchers wanted to see if a probiotic could help reduce inflammation by changing the gut microbiome. They found that Lactobacillus rhamnosus GG (LGG) helped reduce endotoxin levels and biomarkers of inflammation in coronary artery disease (CAD) participants.
The Study Conducted on Patients with Coronary Artery Disease with supplementation of Probiotics
The study was done on 44 people with CAD in a blind trial, which means that the people doing the experiment and the people being experimented on didn’t know what they were getting. They used a randomized clinical design, which means that they randomly assigned some of the participants to get probiotics and some of them to get placebos for three months.
The participants were also given a moderate calorie-restricted diet. The program was designed to help them lose 7-10% of their weight at a rate of 0.5-1 kg per week. The diet consisted of 55% carbohydrate, 10-15% protein, and 25-35% fat.
The Results of the Study
There were no significant differences in weight, Body Mass Index (BMI), and family history of CAD between the groups. At the beginning of the study, there was no significant difference in physical activity level between the two groups. However, there was no change in physical activity levels for those who finished by the end of the study.
Participants who took probiotics and followed a weight loss diet had lower inflammation and metabolic endotoxemia levels than those who did not take probiotics. Researchers also found that people who lost weight by following the diet had better metabolic profiles than those who did not.
This study showed that probiotics (LGG) could help reduce inflammation in people with cardiovascular disease. The study also found that calorie restriction and probiotics together may be more effective than taking probiotics alone.